Skip to main content

Table 3 Summary of adverse events among the included RCTs

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

 CGRP mAb(n/N)Placebo(n/N)I2odds ratio [95% CI]p value
Withdrawal due to AEs38/189835/25040%1.46[0.90,2.37]0.12
Specific AEs
 any serious events1115/18981472/250425%1.02[0.90,1.15]0.79
 dizziness29/83531/13130%1.47[0.87,2.49]0.15
 fatigue36/151539/18250%1.15[0.72,1.83]0.55
 influenza26/123141/17585%0.87[0.53,1.45]0.6
 injection site pain167/1501148/183735%1.44[1.13,1.84]0.004
 migraine12/108617/137911%0.83[0.41,1.71]0.62
 nasopharyngitis115/1817163/24221%0.96[0.75,1.24]0.78
 nausea34/155361/19190%0.68[0.45,1.05]0.08
 upper respiratory tract infection117/1692123/20720%1.25[0.96,1.63]0.1
 urinary tract infection22/127033/15190%0.91[0.53,1.56]0.73